ATE437871T1 - Polymorphe formen von 1-ä4-(5-cyanoindol-3- yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid - Google Patents

Polymorphe formen von 1-ä4-(5-cyanoindol-3- yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid

Info

Publication number
ATE437871T1
ATE437871T1 AT02754627T AT02754627T ATE437871T1 AT E437871 T1 ATE437871 T1 AT E437871T1 AT 02754627 T AT02754627 T AT 02754627T AT 02754627 T AT02754627 T AT 02754627T AT E437871 T1 ATE437871 T1 AT E437871T1
Authority
AT
Austria
Prior art keywords
butylü
carbamoylbenzofuran
cyanoindol
piperazine hydrochloride
polymorphous forms
Prior art date
Application number
AT02754627T
Other languages
English (en)
Inventor
Andreas Bathe
Bernd Helfert
Steffen Neuenfeld
Heike Kniel
Matthias Bartels
Susanne Rudolph
Henning Boettcher
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437871(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE437871T1 publication Critical patent/ATE437871T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
AT02754627T 2001-06-19 2002-06-05 Polymorphe formen von 1-ä4-(5-cyanoindol-3- yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid ATE437871T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113647 2001-06-19
PCT/EP2002/006153 WO2002102794A2 (en) 2001-06-19 2002-06-05 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride

Publications (1)

Publication Number Publication Date
ATE437871T1 true ATE437871T1 (de) 2009-08-15

Family

ID=8177643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754627T ATE437871T1 (de) 2001-06-19 2002-06-05 Polymorphe formen von 1-ä4-(5-cyanoindol-3- yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid

Country Status (30)

Country Link
US (15) US7381726B2 (de)
EP (1) EP1397357B9 (de)
JP (3) JP4624667B2 (de)
KR (1) KR20040012922A (de)
CN (2) CN100384841C (de)
AR (1) AR034595A1 (de)
AT (1) ATE437871T1 (de)
AU (1) AU2002320822B2 (de)
BR (1) BR0210495A (de)
CA (16) CA2782857A1 (de)
CY (1) CY1109447T1 (de)
CZ (2) CZ304471B6 (de)
DE (1) DE60233133D1 (de)
DK (1) DK1397357T3 (de)
EC (1) ECSP044943A (de)
EE (1) EE05454B1 (de)
ES (1) ES2330314T3 (de)
HK (2) HK1066003A1 (de)
HU (1) HU229601B1 (de)
IL (2) IL159426A0 (de)
MX (1) MXPA03011723A (de)
MY (1) MY151087A (de)
NZ (1) NZ530642A (de)
PL (1) PL208708B1 (de)
PT (1) PT1397357E (de)
RU (1) RU2303598C2 (de)
SK (2) SK288162B6 (de)
UA (1) UA76758C2 (de)
WO (1) WO2002102794A2 (de)
ZA (1) ZA200400329B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102219783B (zh) * 2011-05-05 2013-07-03 天津市汉康医药生物技术有限公司 盐酸维拉佐酮及其组合物
CA2854649A1 (en) 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
WO2013088373A1 (en) 2011-12-12 2013-06-20 Ranbaxy Laboratories Limited Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
US9969721B2 (en) 2012-04-12 2018-05-15 Alembic Pharmaceuticals Limited Process for the preparation of vilazodone hydrochloride and its amorphous form
US20150073148A1 (en) * 2012-04-16 2015-03-12 Ranbaxy Laboratories Limited Process for the preparation of crystalline vilazodone hydrochloride
WO2013164794A1 (en) 2012-05-04 2013-11-07 Ranbaxy Laboratories Limited Crystalline forms of vilazodone hydrochloride
WO2013168126A1 (en) 2012-05-11 2013-11-14 Dr.Reddys Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
WO2013175361A1 (en) 2012-05-24 2013-11-28 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
CN102702180A (zh) * 2012-05-25 2012-10-03 吉林三善恩科技开发有限公司 一种维拉佐酮有机药物共晶及其制备方法
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
WO2013182946A2 (en) 2012-06-06 2013-12-12 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
WO2013185209A1 (en) * 2012-06-13 2013-12-19 Apotex Technologies Inc. Forms of vilazodone and processes for the preparation thereof
WO2014028473A1 (en) 2012-08-13 2014-02-20 Assia Chemical Industries Ltd. New salts of vilazodone and solid state forms thereof
WO2014049609A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Novel salts of vilazodone
WO2014049612A2 (en) * 2012-09-27 2014-04-03 Msn Laboratories Limited Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN103772367B (zh) * 2012-10-24 2016-05-25 杭州和泽医药科技有限公司 盐酸维拉佐酮v晶型的制备方法及其应用
CN103772368B (zh) * 2012-10-24 2016-08-03 杭州和泽医药科技有限公司 盐酸维拉佐酮iv晶型的制备方法及其应用
WO2014087428A1 (en) * 2012-12-07 2014-06-12 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of vilazodone and intermediates thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
WO2014178013A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Vilazodone impurities, process for their preparation, and their use as reference standards
WO2014199313A1 (en) 2013-06-12 2014-12-18 Lupin Limited Substantially pure vilazodone hydrochloride and a process thereof
EP2824104A1 (de) 2013-07-12 2015-01-14 Sandoz AG Verfahren zur Herstellung von Form III von Vilazodonhydrochlorid
WO2015019237A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Pharmaceutical composition of vilazodone
WO2015019256A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Pharmaceutical composition of vilazodone and processes of preparation thereof
WO2015037010A1 (en) * 2013-09-13 2015-03-19 Symed Labs Limited Preparation of vilazodone hydrochloride crystalline form iv
CN104610238A (zh) * 2013-11-01 2015-05-13 北京英科博雅科技有限公司 一种维拉佐酮盐酸盐iii晶型新的制备方法
ITMI20131839A1 (it) * 2013-11-06 2015-05-07 Dipharma Francis Srl Co-cristallo di un farmaco antidepressivo
WO2015102019A2 (en) * 2013-12-30 2015-07-09 Msn Laboratories Private Limited Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride
CN105017233A (zh) * 2014-04-23 2015-11-04 天津药物研究院 一种盐酸维拉佐酮晶体、其制备方法、药物组合物和用途
CN105820157B (zh) * 2015-01-09 2021-05-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸维拉佐酮晶型及其制备方法
CN106518854A (zh) * 2016-09-21 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸维拉佐酮晶型ⅳ的制备方法
TR201702103A2 (tr) 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vilazodon hi̇droklorürün tablet formlari
TR201702104A2 (tr) 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇lazodon hi̇droklorür farmasöti̇k bi̇leşi̇mleri̇
CN107098889A (zh) * 2017-03-17 2017-08-29 北京万全德众医药生物技术有限公司 盐酸维拉佐酮药物晶型ⅲ的制备方法
CN109503560A (zh) * 2017-09-14 2019-03-22 北京万全德众医药生物技术有限公司 盐酸维拉佐酮ⅺ晶型的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US532241A (en) * 1895-01-08 Computing-machine
US1294526A (en) * 1917-09-21 1919-02-18 Gerhard Nicolaas Vis Manufacture of sodium carbonate and ammonium sulfate from bisulfate of soda.
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US5521241A (en) * 1994-08-30 1996-05-28 W. R. Grace & Co.-Conn. Styrene copolymer-based plastisol containing glycidyl methacrylate
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
AU2001275910B2 (en) 2000-07-13 2005-06-30 Hydrogen Energy America Llc Method and apparatus for controlled generation of hydrogen by dissociation of water
UA76758C2 (uk) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
US7384020B2 (en) * 2006-06-30 2008-06-10 Amtek System Co., Ltd. Supporting frame structure

Also Published As

Publication number Publication date
HK1066003A1 (en) 2005-03-11
IL159426A (en) 2011-12-29
CA2782515A1 (en) 2002-12-27
CA2782519A1 (en) 2002-12-27
US20100016332A1 (en) 2010-01-21
JP2004534803A (ja) 2004-11-18
US20040147528A1 (en) 2004-07-29
MXPA03011723A (es) 2004-03-19
MY151087A (en) 2014-04-15
ZA200400329B (en) 2005-06-29
PT1397357E (pt) 2009-11-03
CA2782517A1 (en) 2002-12-27
AR034595A1 (es) 2004-03-03
HUP0400236A2 (hu) 2004-06-28
CN100384841C (zh) 2008-04-30
WO2002102794A3 (en) 2003-02-20
WO2002102794A2 (en) 2002-12-27
CA2782862A1 (en) 2002-12-27
DE60233133D1 (de) 2009-09-10
CZ305220B6 (cs) 2015-06-17
US8921375B2 (en) 2014-12-30
US8236804B2 (en) 2012-08-07
ES2330314T3 (es) 2009-12-09
US20110183994A1 (en) 2011-07-28
US20110294824A1 (en) 2011-12-01
JP5714824B2 (ja) 2015-05-07
US8318744B2 (en) 2012-11-27
EP1397357B1 (de) 2009-07-29
US7981894B2 (en) 2011-07-19
HK1116165A1 (de) 2008-12-19
US8673921B2 (en) 2014-03-18
US20110312971A1 (en) 2011-12-22
HU229601B1 (en) 2014-02-28
PL364576A1 (en) 2004-12-13
ECSP044943A (es) 2004-02-26
JP2010132687A (ja) 2010-06-17
CA2782615A1 (en) 2002-12-27
BR0210495A (pt) 2004-08-17
NZ530642A (en) 2006-09-29
US20140275115A1 (en) 2014-09-18
CA2782791A1 (en) 2002-12-27
CA2782857A1 (en) 2002-12-27
CN1516699A (zh) 2004-07-28
US20090023749A1 (en) 2009-01-22
JP4624667B2 (ja) 2011-02-02
CN101139345A (zh) 2008-03-12
CA2782868A1 (en) 2002-12-27
DK1397357T3 (da) 2009-10-05
UA76758C2 (uk) 2006-09-15
HUP0400236A3 (en) 2010-06-28
US20110294825A1 (en) 2011-12-01
CA2782628A1 (en) 2002-12-27
US20210251986A1 (en) 2021-08-19
RU2004100824A (ru) 2005-06-20
CA2782761A1 (en) 2002-12-27
CA2782521A1 (en) 2002-12-27
US7834020B2 (en) 2010-11-16
CN101139345B (zh) 2012-07-11
US20150080411A1 (en) 2015-03-19
CA2451028A1 (en) 2002-12-27
US20170182037A1 (en) 2017-06-29
US20140024658A1 (en) 2014-01-23
SK162004A3 (en) 2004-04-06
AU2002320822B2 (en) 2007-11-15
US20190343831A1 (en) 2019-11-14
EP1397357B9 (de) 2009-11-18
US8193195B2 (en) 2012-06-05
CA2683040A1 (en) 2002-12-27
CA2782865A1 (en) 2002-12-27
KR20040012922A (ko) 2004-02-11
CZ200426A3 (cs) 2004-04-14
PL208708B1 (pl) 2011-05-31
US7381726B2 (en) 2008-06-03
RU2303598C2 (ru) 2007-07-27
SK288334B6 (sk) 2016-02-02
CY1109447T1 (el) 2014-08-13
IL159426A0 (en) 2004-06-01
EE200400019A (et) 2004-04-15
US9624204B2 (en) 2017-04-18
EE05454B1 (et) 2011-08-15
CA2683040C (en) 2012-09-25
CA2782494A1 (en) 2002-12-27
SK288162B6 (sk) 2014-03-04
EP1397357A2 (de) 2004-03-17
US20110190317A1 (en) 2011-08-04
US20130102616A1 (en) 2013-04-25
US8927552B2 (en) 2015-01-06
JP2010132688A (ja) 2010-06-17
CA2782623A1 (en) 2002-12-27
CA2451028C (en) 2012-07-17
CZ304471B6 (cs) 2014-05-21
JP5411734B2 (ja) 2014-02-12

Similar Documents

Publication Publication Date Title
ATE437871T1 (de) Polymorphe formen von 1-ä4-(5-cyanoindol-3- yl)butylü-4-(2-carbamoylbenzofuran-5-yl) piperazin-hydrochlorid
NO20020307D0 (no) N-(indolkarbonyl)piperazinderivater
ATE366735T1 (de) Polymorphe formen eines epothilon-analogons
DE60310592D1 (de) Geneigte schraubenfedern verschiedener ausführung
DE60233399D1 (de) Erzerrung zweiter ordnung
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE60236226D1 (de) Verbesserung der Altersweitsichtigkeit
DK1325008T3 (da) Piperazinderivater
DK1472255T3 (da) Aza-arylpiperaziner
DE60234696D1 (de) N-(3-amino-2-hydroxy-propyl)substituierte alkylamidverbindungen
NO20035522D0 (no) Kinuklidin-substituerte multisykliske heteroaryler for behandling av sykdom
NO20041689L (no) Substituerte tioacetamider
DE60210107D1 (de) Elastische mischungen
DE02784674T1 (de) Quantifizierung von polypeptiden
DE50209888D1 (de) Druckverfahren
ATE329177T1 (de) Reibungsdämpfendes bein
ATE391502T1 (de) Kristalline formen von fluvastatin-natrium
NO20041449L (no) Krystallinformer av valasyklovir-hydroklorid
ATE424414T1 (de) Chimere somatostatin-dopamin-analoga
DE50200615D1 (de) Geminitenside
NO20034949D0 (no) Sulfonamider
ATE495169T1 (de) Toluol-solvat von darifenacin
DE50107986D1 (de) Luftfederbalg
DE50200250D1 (de) Geminitenside
DE60200863D1 (de) Doppeltelezentrisches Objektiv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397357

Country of ref document: EP